Sigma-Aldrich s TargeTron Gene Knockout System, Celliance s Hybri-CYTE, and Peakdale Molecular s Peakexplorer GPCR Library | GenomeWeb

Sigma-Aldrich has announced the commercialization of the TargeTron Gene Knockout System. TargeTron provides a robust and simple method for site-specific disruption of DNA sequences within a host cell genome, Sigma-Aldrich said. The technology exploits the retrohoming ability of group II introns in order to “target” the exact position of gene disruption, the company said. The technology was developed by Alan Lambowitz from the University of Texas at Austin, and licensed from Ingex, Sigma-Aldrich said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.